| Literature DB >> 22666502 |
Raphael Lis1, Cyril Touboul, Christophe M Raynaud, Joel A Malek, Karsten Suhre, Massoud Mirshahi, Arash Rafii.
Abstract
Tumor microenvironment is an important actor of ovarian cancer progression but the relations between mesenchymal cells and ovarian cancer cells remain unclear. The objective of this study was to determine the ovarian cancer cells' biological modifications induced by mesenchymal cells. To address this issue, we used two different ovarian cancer cell lines (NIH:OVCAR3 and SKOV3) and co-cultured them with mesenchymal cells. Upon co-culture the different cell populations were sorted to study their transcriptome and biological properties. Transcriptomic analysis revealed three biological-function gene clusters were enriched upon contact with mesenchymal cells. These were related to the increase of metastatic abilities (adhesion, migration and invasion), proliferation and chemoresistance in vitro. Therefore, contact with the mesenchymal cell niche could increase metastatic initiation and expansion through modification of cancer cells. Taken together these findings suggest that pathways involved in hetero-cellular interaction may be targeted to disrupt the acquired pro-metastatic profile.Entities:
Mesh:
Year: 2012 PMID: 22666502 PMCID: PMC3364218 DOI: 10.1371/journal.pone.0038340
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Modification of OCC transcriptome upon interaction with MC. A.
Contour plot showing a typical discrimination of OCC and MC by FACS. OCC were defined as eGFP+EpCAM+ (green population) whereas MCs were defined as eGFP-EpCAM- (dark grey population). B. PCA analysis for the ovarian cancer cells lines alone or post-contact with the Mesenchymal cells.
MC contact enriches biological function gene clusters.
| OVCAR3-eGFP | SKOV3-eGFP | |||||||
| Biological function | ID | Gene Name | Gene Symbol | Fold Change relative to the control | ID | Gene Name | Gene Symbol | Fold Change relative to the control |
| Metastasis | 221577_x_at | Growth Diffentiation Factor 15 | GDF15 |
| 206336_at | Chemokine (C-X-C motif) ligand 6 | CXCL6 |
|
| 217678_at | Solute carrier family 7 anionic amino acid transporter light chain, xc-system), member 11 | SLC7A11 |
| 201438_at | Collagen alpha-3(VI) chain | COL6A3 |
| |
| 202672_s_at | Activating transcription factor 3 | ATF3 |
| 212942_s_at | KIAA1199 | KIAA1199 |
| |
| 201010_s_at | Thioredoxin interacting protein | TXNIP |
| 216598_s_at | Chemokine (C-C motif) ligand 2 | CCL2 |
| |
| 212314_at | sel-1 suppressor of lin-12-like 3 | SEL1L3 |
| 228128_x_at | Pregnancy-associated plasma protein A | PAPPA |
| |
| 200953_s_at | cyclin D2 | CCND2 |
| 205828_at | Matrix metalloproteinase-3 | MMP3 |
| |
| 210105_s_at | FYN oncogene related to SRC, FGR, YES | FYN |
| |||||
| 201438_at | Collagen alpha-3(VI) chain | COL6A3 |
| |||||
| 211719_x_at | Fibronectin 1 | FN1 |
| |||||
| Proliferation of cell lines | 221577_x_at | Growth Diffentiation Factor 15 | GDF15 |
| 1556499_s_at | Collagen, type I, alpha 1 | COL1A1 |
|
| 217678_at | Solute carrier family 7 anionic amino acid transporter light chain, xc-system), member 11 | SLC7A11 |
| 202291_s_at | Matrix gla protein | MGP |
| |
| 206085_s_at | CTH |
| 216598_s_at | Chemokine (C-C motif) ligand 2 | CCL2 |
| ||
| 202672_s_at | Activating transcription factor 3 | ATF3 |
| 204051_s_at | Secreted frizzled-related protein 4 | SFRP4 |
| |
| 201010_s_at | thioredoxin interacting protein | TXNIP |
| 228128_x_at | Pregnancy-associated plasma protein A | PAPPA |
| |
| 208763_s_at | TSC22 domain family, member 3 | TSC22D3 |
| 228335_at | Claudin-11 | CLDN11 |
| |
| 203725_at | growth arrest and DNA-damage-inducible, alpha | GADD45A |
| 212667_at | Secreted Protein Acidic and Rich in Cysteine | SPARC |
| |
| 203543_s_at | Kruppel-like factor 9 | KLF9 |
| 205828_at | Matrix metalloproteinase-3 | MMP3 |
| |
| 203140_at | B-cell CLL/lymphoma 6 | BCL6 |
| 209821_at | Interleukin 33 | IL33 |
| |
| 200953_s_at | cyclin D2 | CCND2 |
| |||||
| 212501_at | CCAAT/enhancer binding protein (C/EBP), beta | CEBPB (includes EG:1051) |
| |||||
| 210105_s_at | FYN oncogene related to SRC, FGR, YES | FYN |
| |||||
| 202581_at | heat shock 70kDa protein 1A/1B | HSPA1A/HSPA1B |
| |||||
| 1556499_s_at | Collagen, type I, alpha 1 | COL1A1 |
| |||||
| 211719_x_at | Fibronectin 1 | FN1 |
| |||||
| 200665_s_at | Secreted Protein Acidic and Rich in Cysteine | SPARC |
| |||||
| Cell Death of tumor cell line | 221577_x_at | Growth Diffentiation Factor 15 | GDF15 |
| 216598_s_at | Chemokine (C-C motif) ligand 2 | CCL2 |
|
| 205047_s_at | asparagie synthetase (glutamine-hydrolyzing) | ASNS |
| 204051_s_at | Secreted frizzled-related protein 4 | SFRP4 |
| |
| 217678_at | Solute carrier family 7 anionic amino acid transporter light chain, xc-system), member 11 | SLC7A11 |
| 212667_at | Secreted Protein Acidic and Rich in Cysteine | SPARC |
| |
| 202672_s_at | Activating transcription factor 3 | ATF3 |
| 208998_at | Uncoupling Protein 2 | UCP2 |
| |
| 209383_at | DNA-damage-inducible transcript 3 | DDIT3 |
| |||||
| 203725_at | growth arrest and DNA-damage-inducible, alpha |
| ||||||
| 202887_s_at | DNA-damage-inducible transcript 4 | DDIT4 |
| |||||
| 203140_at | B-cell CLL/lymphoma 6 | BCL6 |
| |||||
| 212501_at | CCAAT/enhancer binding protein (C/EBP), beta | CEBPB (includes EG:1051) |
| |||||
| 202581_at | heat shock 70kDa protein 1A/1B | HSPA1A/HSPA1B |
| |||||
| 210338_s_at | heat shock 70kDa protein 8 | HSPA8 |
| |||||
| 211719_x_at | Fibronectin 1 | FN1 |
| |||||
| 200665_s_at | Secreted Protein Acidic and Rich in Cysteine | SPARC |
| |||||
Table showing the biological clusters identified by IPA analysis. p-values for the different clusters are: “Metastasis” (NIH:OVCAR3, p = 6.48*10−6; SKOV3, p = 5.42*10−5), “Proliferation of cell lines” (NIH:OVCAR3, p = 4.36.48*10−7; SKOV3, p = 6.79*10−6) and “Cell death of tumor cell line” (NIH:OVCAR3, p = 5.68*10−8; SKOV3, p = 7.62*10−5). These clusters were shared between NIH:OVCAR3-eGFP and SKOV3-eGFP.
Figure 2MCs increase OCC metastasis biological function: adherence, migration and invasion.
A. OCC-eGFP (NIH:OVCAR3, left chart and SKOV3, right chart) were seeded on a Matrigel (BD Biosciences)-coated well for 10 min, 15 min, 30 min and 1 hour. Increased adherence to the ECM is observed when OCC were preemptively cultivated with MC (light grey bars) compared to the control (dark grey bars). B. Scheme representing the invasion and migration assay. C. Sorted OCC were seeded on (un) coated transwells and GFP signal of each well under the coated membrane was acquired after 24 h. Increased migration and invasion through the ECM is observed when OCC were preemptively cultivated with MC (light grey bars) compared to the control (dark grey bars). SEM are represented, n = 3, | p<0.05 t-Student Test.
Figure 3MC sustains OCC proliferation in a serum free cytokine free context. A.
OCC were cultivated on a MC expressing mOrange or direclty on the plastic dish. Proliferation assay was carried out in a serum free-cytokine free media. Pictures were taken every two days, and GFP cells were quantified. B. Detail of the well on day 14, we can notice OCC display a normal morphology. C. Chart displaying cell count carried over 14 days. OVCAR3 eGFP when seeded on a MC are able to sustain cell cycle in a serum free cytokine free media. Similar results were obtained with SKOV3 (data not shown). SEM are represented, n = 3, | p<0.05 t-Student Test.
Figure 4MC protects OCC from chemotherapy induced cell death.
A. Explanative scheme of FACS analysis. B. OCC or OCC co-cultivated with MSC were treated for 48 hours with 90 µM of Cisplatin and 6 nm of Paclitaxel. Cell types were discriminated by FACS using GFP as a cancer cell marker, and CD73 as an MC marker. Cell death analysis was carried out using the dual Calcein/Live Dead staining. C. Quantitation of cell death analysis experiments. OCC display a resistance to conventional chemotherapy treatment when co-cultivated with MC compared to the control. SEM are represented, n = 3, | p<0.05 t-Student Test.